Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has completed its safety review of the IND application and has concluded that the proof-of-concept Phase II combination trial with its lead drug candidate lanifibranor and the SGLT2 inhibitor empagliflozin1 in patients with Type 2 Diabetes (T2D) and non-cirrhotic NASH may proceed.
https://finance.yahoo.com/news/inventiva-announces-ind-application-phase-070000961.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.